Cargando…

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma

PURPOSE: To evaluate the effect of escalated dose radiation therapy (EDR, defined as doses >50.4 Gy in 28 fractions [59.5 Gy BED]) on overall survival (OS), freedom from local progression (FFLP), and freedom from distant progression (FFDP) of patients with unresectable extrahepatic cholangiocarci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elganainy, Dalia, Holliday, Emma B., Taniguchi, Cullen M., Smith, Grace L., Shroff, Rachna, Javle, Milind, Raghav, Kanwal, Kaseb, Ahmed, Aloia, Thomas A., Vauthey, Jean Nicolas, Tzeng, Ching‐Wei D., Herman, Joseph M., Koong, Albert C., Krishnan, Sunil X., Minsky, Bruce D., Crane, Christopher H., Das, Prajnan, Koay, Eugene J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198206/ https://www.ncbi.nlm.nih.gov/pubmed/30152073 http://dx.doi.org/10.1002/cam4.1734

Ejemplares similares

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
por: De, Brian, et al.
Publicado: (2023)

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
por: De, Brian, et al.
Publicado: (2021)

Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus
por: Holliday, Emma B., et al.
Publicado: (2017)

Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma
por: De, Brian, et al.
Publicado: (2021)

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer
por: Moningi, Shalini, et al.
Publicado: (2022)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
por: Manzar, Gohar Shahwar, et al.
Publicado: (2022)

Dose escalation for locally advanced pancreatic cancer: How high can we go?
por: Colbert, Lauren E., et al.
Publicado: (2018)

Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis
por: Dodoo, Grace N, et al.
Publicado: (2023)

Hyperfractionated abdominal reirradiation for gastrointestinal malignancies
por: Hunt, Andrew, et al.
Publicado: (2018)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer
por: Wang, Charles X., et al.
Publicado: (2022)

Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration–based image guidance
por: Choi, Gye Won, et al.
Publicado: (2019)

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
por: Koay, Eugene J., et al.
Publicado: (2019)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling
por: Javle, Milind, et al.
Publicado: (2013)

Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network
por: Augustyn, Alexander, et al.
Publicado: (2021)

Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
por: Moningi, Shalini, et al.
Publicado: (2019)

IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer
por: Moningi, Shalini, et al.
Publicado: (2019)

Dose Escalation for Pancreas SBRT: Potential and Limitations of using Daily Online Adaptive Radiation Therapy and an Iterative Isotoxicity Automated Planning Approach
por: Rhee, Dong Joo, et al.
Publicado: (2023)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
por: Colbert, Lauren E., et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
por: Amer, Ahmed M., et al.
Publicado: (2018)

Reirradiation to the abdomen for gastrointestinal malignancies
por: Haque, Waqar, et al.
Publicado: (2009)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
por: Inoue, Tadahisa, et al.
Publicado: (2022)

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
por: Spencer, Kristen, et al.
Publicado: (2023)

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer
por: Cazacu, Irina M., et al.
Publicado: (2023)

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience
por: Bagley, Alexander F., et al.
Publicado: (2022)

Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era
por: Abi Jaoude, Joseph, et al.
Publicado: (2021)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Surgical Management of Localized Hepatocellular Carcinoma in Times of Crisis: A Strategic Approach to Resource Utilization
por: Tran Cao, Hop, et al.
Publicado: (2020)

Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al
por: Noticewala, Sonal S., et al.
Publicado: (2020)

Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer
por: Moningi, Shalini, et al.
Publicado: (2020)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
por: Javle, Milind M, et al.
Publicado: (2010)

The Management of Extrahepatic Portal Vein Aneurysms: Observe or Treat?
por: Feliciano, Philip D., et al.
Publicado: (1996)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_buij1vatick084bcaccupknkmq